No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Digital brain health solutions developer Cambridge Cognition announced the creation of a scientific advisory board on Thursday.
The AIM-traded firm said the board aimed to offer expert guidance and market insights, with a particular emphasis on emerging trends such as the incorporation of blood-based biomarkers, collaborative opportunities for computerised cognitive assessments, and the importance of diverse populations in clinical trials.
It said the board would also play a pivotal role in reviewing and advising on product strategies, scientific approaches, and evidence generation for regulatory and data strategies.
Comprising experts in CNS-related disorders, clinical development, and academia, the board would dedicated to advancing brain health initiatives.
Chaired by Liam Kaufman, vice president of clinical science and former CEO of Winterlight Labs, the board also included professor Judith Jaeger, PhD, bringing over 35 years of experience in neuropsychology and psychopathology.
Professor Jaeger serves as the owner and president of CognitionMetrics, offering consultancy services to the pharmaceutical industry and a distinguished academic career at Albert Einstein College of Medicine, New York.
Another notable member would be professor John Harrison, a cognition expert and chief scientific officer at Scottish Brain Sciences.
With more than 25 years of experience, professor Harrison had assisted numerous CNS drug development organisations and made significant contributions to Alzheimer's disease research and psychiatric indications, including the development of the Neuropsychological Test Battery (NTB).
Completing the trio of founding members would be Francesca Cormack, PhD, chief scientist at Cambridge Cognition.
"With the emergence of disease-modifying therapies for Alzheimer's disease and progress in many other conditions, as well as the evolution of digital cognitive assessments, the landscape for CNS clinical research is rapidly evolving," said chief executive officer Matthew Stork.
"Establishing the scientific advisory board underscores our dedication to advancing the alignment of emerging trends in the sector.
"The board aims to deepen our understanding of customer requirements, assisting us to adapt rapidly to the evolving landscape while expanding the capabilities of our solutions."
At 1444 GMT, shares in Cambridge Cognition Holdings were up 0.18% at 55.6p.
Reporting by Josh White for Sharecast.com.
